| Year |
Citation |
Score |
| 2024 |
Anwar A, Lepore C, Czerniecki BJ, Koski GK, Showalter LE. PIM kinase inhibitor AZD1208 in conjunction with Th1 cytokines potentiate death of breast cancer cellsin vitrowhile also maximizing suppression of tumor growthin vivo when combined with immunotherapy. Cellular Immunology. 104805. PMID 38244265 DOI: 10.1016/j.cellimm.2024.104805 |
0.578 |
|
| 2022 |
Ramamoorthi G, Kodumudi K, Snyder C, Grover P, Zhang H, Greene MI, Basu A, Gallen C, Wiener D, Costa RLB, Han HS, Koski G, Czerniecki BJ. Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma. Journal For Immunotherapy of Cancer. 10. PMID 35710296 DOI: 10.1136/jitc-2022-004841 |
0.416 |
|
| 2021 |
Basu A, Albert GK, Awshah S, Datta J, Kodumudi KN, Gallen C, Beyer A, Smalley KSM, Rodriguez PC, Dukett DR, Forsyth PA, Soyano A, Koski GK, Lima Barros Costa R, Han H, et al. Identification of immunogenic MHC class II human HER3 peptides that mediate anti-HER3 CD4+ Th1 responses and potential use as a cancer vaccine. Cancer Immunology Research. PMID 34785506 DOI: 10.1158/2326-6066.CIR-21-0454 |
0.409 |
|
| 2021 |
Showalter LE, Czerniecki BJ, Kodumudi K, Koski GK. Murine Dendritic Cells Grown in Serum-Free Culture Show Potent Therapeutic Activity when Loaded with Novel Th Epitopes in an Orthotopic Model of HER2 Breast Cancer. Vaccines. 9. PMID 34579275 DOI: 10.3390/vaccines9091037 |
0.742 |
|
| 2021 |
Ghimirey N, Steele C, Czerniecki BJ, Koski GK, Showalter LE. Sunitinib Combined with Th1 Cytokines Potentiates Apoptosis in Human Breast Cancer Cells and Suppresses Tumor Growth in a Murine Model of HER-2 Breast Cancer. International Journal of Breast Cancer. 2021: 8818393. PMID 33936816 DOI: 10.1155/2021/8818393 |
0.767 |
|
| 2021 |
Jia Y, Kodumudi KN, Ramamoorthi G, Basu A, Snyder C, Wiener D, Pilon-Thomas S, Zhang H, Greene MI, Mo Q, Tong Z, Chen YZ, Costa RLB, Han H, Lee C, ... ... Koski G, et al. Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 33412308 DOI: 10.1016/j.ymthe.2020.12.037 |
0.496 |
|
| 2020 |
Showalter L, Czerniecki BJ, Koski GK. Th1 cytokines in conjunction with pharmacological Akt inhibition potentiate apoptosis of breast cancer cells and suppress tumor growth . Oncotarget. 11: 2873-2888. PMID 32774769 DOI: 10.18632/Oncotarget.27556 |
0.764 |
|
| 2020 |
Oechsle CM, Showalter LE, Novak CM, Czerniecki BJ, Koski GK. Statin Drugs Plus Th1 Cytokines Potentiate Apoptosis and Ras Delocalization in Human Breast Cancer Lines and Combine with Dendritic Cell-Based Immunotherapy to Suppress Tumor Growth in a Mouse Model of HER-2 Disease. Vaccines. 8. PMID 32041347 DOI: 10.3390/Vaccines8010072 |
0.764 |
|
| 2019 |
Krishnan A, Koski G, Mou X. Characterization of microcystin-induced apoptosis in HepG2 hepatoma cells. Toxicon : Official Journal of the International Society On Toxinology. PMID 31734250 DOI: 10.1016/J.Toxicon.2019.11.003 |
0.381 |
|
| 2019 |
Namjoshi P, Showalter L, Czerniecki BJ, Koski GK. T-helper 1-type cytokines induce apoptosis and loss of HER-family oncodriver expression in murine and human breast cancer cells. Oncotarget. 10: 6006-6020. PMID 31666931 DOI: 10.18632/oncotarget.10298 |
0.548 |
|
| 2019 |
Showalter LE, Oechsle C, Ghimirey N, Steele C, Czerniecki BJ, Koski GK. Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib. Plos One. 14: e0210209. PMID 30657766 DOI: 10.1371/Journal.Pone.0210209 |
0.767 |
|
| 2017 |
Lowenfeld L, Zaheer S, Oechsle C, Fracol M, Datta J, Xu S, Fitzpatrick E, Roses RE, Fisher CS, McDonald ES, Zhang PJ, DeMichele A, Mick R, Koski GK, Czerniecki BJ. Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ER(pos)/HER2(pos) early breast cancer. Oncoimmunology. 6: e1207032. PMID 28932627 DOI: 10.1080/2162402X.2016.1207032 |
0.406 |
|
| 2017 |
Rosenthal KS, Stone S, Koski G, Zimmerman DH. LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model. Journal of Immunology Research. 2017: 3613505. PMID 28459074 DOI: 10.1155/2017/3613505 |
0.531 |
|
| 2017 |
Huang E, Showalter L, Xu S, Czernliecki BJ, Koski GK. Calcium mobilizing treatment acts as a co-signal for TLR-mediated induction of Interleukin-12 (IL-12p70) secretion by murine bone marrow-derived dendritic cells. Cellular Immunology. PMID 28190517 DOI: 10.1016/J.Cellimm.2017.01.010 |
0.711 |
|
| 2016 |
Namjoshi P, Showalter L, Czerniecki BJ, Koski GK. T-helper 1-type cytokines induce apoptosis and loss of HER-family oncodriver expression in murine and human breast cancer cells. Oncotarget. PMID 27374107 DOI: 10.18632/oncotarget.10298 |
0.552 |
|
| 2015 |
Datta J, Rosemblit C, Berk E, Showalter L, Namjoshi P, Mick R, Lee KP, Brod AM, Yang RL, Kelz RR, Fitzpatrick E, Hoyt C, Feldman MD, Zhang PJ, Xu S, ... Koski GK, et al. Progressive loss of anti-HER2 CD4(+) T-helper type 1 response in breast tumorigenesis and the potential for immune restoration. Oncoimmunology. 4: e1022301. PMID 26451293 DOI: 10.1080/2162402X.2015.1022301 |
0.504 |
|
| 2013 |
Paustian C, Taylor P, Johnson T, Xu M, Ramirez N, Rosenthal KS, Shu S, Cohen PA, Czerniecki BJ, Koski GK. Extracellular ATP and Toll-like receptor 2 agonists trigger in human monocytes an activation program that favors T helper 17. Plos One. 8: e54804. PMID 23382974 DOI: 10.1371/Journal.Pone.0054804 |
0.453 |
|
| 2012 |
Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, Koski G, Czerniecki BJ. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer. 118: 4354-62. PMID 22252842 DOI: 10.1002/Cncr.26734 |
0.467 |
|
| 2012 |
Koski GK, Koldovsky U, Xu S, Mick R, Sharma A, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, Czerniecki BJ. A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. Journal of Immunotherapy (Hagerstown, Md. : 1997). 35: 54-65. PMID 22130160 DOI: 10.1097/CJI.0b013e318235f512 |
0.433 |
|
| 2011 |
Paustian C, Caspell R, Johnson T, Cohen PA, Shu S, Xu S, Czerniecki BJ, Koski GK. Effect of multiple activation stimuli on the generation of Th1-polarizing dendritic cells. Human Immunology. 72: 24-31. PMID 20951755 DOI: 10.1016/j.humimm.2010.10.004 |
0.479 |
|
| 2010 |
Taylor PR, Koski GK, Paustian CC, Bailey E, Cohen PA, Moore FB, Zimmerman DH, Rosenthal KS. J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells. Vaccine. 28: 5533-42. PMID 20600501 DOI: 10.1016/J.Vaccine.2010.06.043 |
0.451 |
|
| 2010 |
Taylor PR, Paustian CC, Koski GK, Zimmerman DH, Rosenthal KS. Maturation of dendritic cell precursors into IL12-producing DCs by J-LEAPS immunogens. Cellular Immunology. 262: 1-5. PMID 20163792 DOI: 10.1016/J.Cellimm.2010.01.003 |
0.357 |
|
| 2010 |
Lee WT, Tan C, Koski G, Shu S, Cohen P. Immunotherapy using allogeneic squamous cell tumor-dendritic cell fusion hybrids. Head & Neck. 32: 1209-16. PMID 20054852 DOI: 10.1002/Hed.21323 |
0.353 |
|
| 2010 |
Cho EI, Tan C, Koski GK, Cohen PA, Shu S, Lee WT. Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines. Head & Neck. 32: 700-7. PMID 19908319 DOI: 10.1002/hed.21241 |
0.344 |
|
| 2010 |
Taylor P, Koski G, Bailey E, Zimmerman D, Rosenthal KS. J-LEAPS Vaccines Mature Mouse Bone Marrow Cells to Dendritic Cells-1 (DC1) which can Deliver Protective Immunity Clinical Immunology. 135: S32. DOI: 10.1016/J.Clim.2010.03.098 |
0.461 |
|
| 2008 |
Roses RE, Xu S, Xu M, Koldovsky U, Koski G, Czerniecki BJ. Differential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonists. Journal of Immunology (Baltimore, Md. : 1950). 181: 5120-7. PMID 18802116 DOI: 10.4049/Jimmunol.181.7.5120 |
0.507 |
|
| 2008 |
Cohen PA, Koski GK, Czerniecki BJ, Bunting KD, Fu XY, Wang Z, Zhang WJ, Carter CS, Awad M, Distel CA, Nagem H, Paustian CC, Johnson TD, Tisdale JF, Shu S. STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells. Blood. 112: 1832-43. PMID 18577706 DOI: 10.1182/Blood-2007-12-130138 |
0.416 |
|
| 2008 |
Zheng R, Cohen PA, Paustian CA, Johnson TD, Lee WT, Shu S, Koski GK. Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12. Cancer Research. 68: 4045-9. PMID 18519662 DOI: 10.1158/0008-5472.CAN-07-6669 |
0.467 |
|
| 2008 |
Koski GK, Cohen PA, Roses RE, Xu S, Czerniecki BJ. Reengineering dendritic cell-based anti-cancer vaccines. Immunological Reviews. 222: 256-76. PMID 18364007 DOI: 10.1111/j.1600-065X.2008.00617.x |
0.426 |
|
| 2008 |
Tamai H, Watanabe S, Zheng R, Deguchi K, Cohen PA, Koski GK, Shu S. Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic-tumor hybrid vaccination and adoptive transfer of sensitized T cells. Clinical Immunology (Orlando, Fla.). 127: 66-77. PMID 18262845 DOI: 10.1016/j.clim.2007.12.001 |
0.364 |
|
| 2008 |
Roses RE, Xu M, Koski GK, Czerniecki BJ. Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer. Oncogene. 27: 200-7. PMID 18176601 DOI: 10.1038/sj.onc.1210909 |
0.377 |
|
| 2008 |
Zheng R, Cohen PA, Paustian CA, Johnson TD, Lee WT, Shu S, Koski GK. IL‐12‐dependent Enhancement of Cancer Vaccine Therapy Using Paired TLR Agonist Adjuvants The Faseb Journal. 22: 525-525. DOI: 10.1096/fasebj.22.2_supplement.525 |
0.335 |
|
| 2007 |
Czerniecki BJ, Roses RE, Koski GK. Development of vaccines for high-risk ductal carcinoma in situ of the breast. Cancer Research. 67: 6531-4. PMID 17638860 DOI: 10.1158/0008-5472.CAN-07-0878 |
0.348 |
|
| 2007 |
Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, Nisenbaum H, Pasha T, Xu M, Fox KR, Weinstein S, Orel SG, Vonderheide R, Coukos G, DeMichele A, et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Research. 67: 1842-52. PMID 17293384 DOI: 10.1158/0008-5472.Can-06-4038 |
0.504 |
|
| 2007 |
Roses R, Xu M, Xu S, Koldovsky U, Son G, Koski G, Czerniecki B. Working Towards the Development of Vaccines for the Treatment and Prevention of Early Breast Cancer Current Cancer Therapy Reviews. 3: 97-107. DOI: 10.2174/157339407780618461 |
0.335 |
|
| 2007 |
Czerniecki BJ, Xu M, Koski G. Neoadjuvant Therapy for HER-2/neu–Expressing Ductal Carcinoma in Situ Using Type 1 Polarized Dendritic Cell Vaccines Breast Diseases: a Year Book Quarterly. 17: 320-323. DOI: 10.1016/S1043-321X(07)80102-0 |
0.404 |
|
| 2006 |
Xu S, Koldovsky U, Xu M, Wang D, Fitzpatrick E, Son G, Koski G, Czerniecki BJ. High-avidity antitumor T-cell generation by toll receptor 8-primed, myeloid- derived dendritic cells is mediated by IL-12 production. Surgery. 140: 170-8. PMID 16904966 DOI: 10.1016/J.Surg.2006.03.006 |
0.514 |
|
| 2004 |
Koski GK, Karikó K, Xu S, Weissman D, Cohen PA, Czerniecki BJ. Cutting edge: innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells. Journal of Immunology (Baltimore, Md. : 1950). 172: 3989-93. PMID 15034009 DOI: 10.4049/Jimmunol.172.7.3989 |
0.371 |
|
| 2004 |
Koski G, Kariko K, Xu S, Weissman D, Czerniecki B. Bacterial Single-Stranded RNA and Its Structural Mimics Activate High-Level Interleukin-12 Secretion by Human Dendritic Cells Journal of Immunotherapy. 27: S25. DOI: 10.1097/00002371-200411000-00092 |
0.337 |
|
| 2003 |
Bedrosian I, Mick R, Xu S, Nisenbaum H, Faries M, Zhang P, Cohen PA, Koski G, Czerniecki BJ. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 3826-35. PMID 14551301 DOI: 10.1200/Jco.2003.04.042 |
0.397 |
|
| 2003 |
Xu S, Koski GK, Faries M, Bedrosian I, Mick R, Maeurer M, Cheever MA, Cohen PA, Czerniecki BJ. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism Journal of Immunology. 171: 2251-2261. PMID 12928369 |
0.374 |
|
| 2002 |
Lyakh LA, Koski GK, Young HA, Spence SE, Cohen PA, Rice NR. Adenovirus type 5 vectors induce dendritic cell differentiation in human CD14(+) monocytes cultured under serum-free conditions. Blood. 99: 600-8. PMID 11781244 DOI: 10.1182/blood.V99.2.600 |
0.322 |
|
| 2001 |
Koski GK, Lyakh LA, Rice NR. Rapid lipopolysaccharide-induced differentiation of CD14(+) monocytes into CD83(+) dendritic cells is modulated under serum-free conditions by exogenously added IFN-gamma and endogenously produced IL-10. European Journal of Immunology. 31: 3773-81. PMID 11745398 DOI: 10.1002/1521-4141(200112)31:12<3773::AID-IMMU3773>3.0.CO;2-W |
0.407 |
|
| 2001 |
Faries MB, Bedrosian I, Xu S, Koski G, Roros JG, Moise MA, Nguyen HQ, Engels FH, Cohen PA, Czerniecki BJ. Calcium signaling inhibits interleukin-12 production and activates CD83(+) dendritic cells that induce Th2 cell development. Blood. 98: 2489-97. PMID 11588047 DOI: 10.1182/Blood.V98.8.2489 |
0.526 |
|
| 2000 |
Lyakh LA, Koski GK, Telford W, Gress RE, Cohen PA, Rice NR. Bacterial lipopolysaccharide, TNF-alpha, and calcium ionophore under serum-free conditions promote rapid dendritic cell-like differentiation in CD14+ monocytes through distinct pathways that activate NK-kappa B. Journal of Immunology (Baltimore, Md. : 1950). 165: 3647-55. PMID 11034368 DOI: 10.4049/JIMMUNOL.165.7.3647 |
0.304 |
|
| 2000 |
Bedrosian I, Roros JG, Xu S, Nguyen HQ, Engels F, Faries MB, Koski GK, Cohen PA, Czerniecki BJ. Granulocyte-macrophage colony-stimulating factor, interleukin-2, and interleukin-12 synergize with calcium ionophore to enhance dendritic cell function. Journal of Immunotherapy (Hagerstown, Md. : 1997). 23: 311-20. PMID 10838660 DOI: 10.1097/00002371-200005000-00004 |
0.343 |
|
| Show low-probability matches. |
